SU0268

SU0268 is a selective small molecule inhibitor of 8-oxoguanine DNA glycosylase 1 (OGG1), an enzyme primarily known for its role in the base excision repair (BER) pathway by removing 8-oxoguanine (8-oxoG) lesions from DNA. Beyond its repair function, OGG1 acts as a mediator of inflammation; SU0268 blocks this pro-inflammatory signaling by preventing OGG1 from recruiting transcription factors like STAT1 to the promoters of cytokine genes. Developed by researchers at Stanford University, SU0268 has demonstrated the ability to suppress the expression of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α in models of sickle cell disease (SCD) and other inflammatory conditions. It is currently being investigated as a potential therapeutic approach to control sickle cell inflammation and oxidative stress-related pathology.